<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36916989</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Cathelicidins Target HSP60 To Restrict CVB3 Transmission via Disrupting the Exosome and Reducing Cardiomyocyte Apoptosis.</ArticleTitle><Pagination><StartPage>e0143322</StartPage><MedlinePgn>e0143322</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01433-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.01433-22</ELocationID><Abstract><AbstractText>Cathelicidin antimicrobial peptides (mouse, CRAMP; human, LL-37) have broad-spectrum antiviral activities against enveloped viruses, but their mechanisms of action against nonenveloped viruses remain to be elucidated. Coxsackievirus B3 (CVB3), a member of nonenveloped virus belonging to the <i>Enterovirus</i> genus of <i>Picornaviridae</i>, is an important pathogen of viral myocarditis and dilated cardiomyopathy. Here, we observed that cardiac CRAMP expression was significantly upregulated in mice after CVB3 infection. The administration of CRAMP or LL-37 markedly suppressed CVB3 infection in mice, and CRAMP deficiency increased the susceptibility of mice to CVB3. CRAMP and LL-37 inhibited CVB3 replication in primary cardiomyocytes. However, they did not inactivate CVB3 particles and did not regulate the response of cardiomyocytes against CVB3 infection. Intriguingly, they inhibited CVB3 transmission through the exosome, but not virus receptor. In detail, CRAMP and LL-37 directly induced the lysis of exosomes by interfering with exosomal heat shock protein 60 (HSP60) and then blocked the diffusion of exosomes to recipient cells and inhibited the establishment of productive infection by exosomes. In addition, the interaction of CRAMP and LL-37 with HSP60 simultaneously inhibited HSP60-induced apoptosis in cardiomyocytes and reduced HSP60-enhanced CVB3 replication. Our findings reveal a novel mechanism of cathelicidins against viral infection and provide a new therapeutic strategy for CVB3-induced viral myocarditis. <b>IMPORTANCE</b> The relative mechanisms that cathelicidin antimicrobial peptides use to influence nonenveloped virus infection are unclear. We show here that cathelicidin antimicrobial peptides (CRAMP and LL-37) directly target exosomal HSP60 to destroy exosomes, which in turn block the diffusion of exosomes to recipient cardiomyocytes and reduced HSP60-induced apoptosis, thus restricting coxsackievirus B3 infection. Our results provide new insights into the mechanisms cathelicidin antimicrobial peptides use against viral infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Chunjing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hui</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Affiliated Guangji Hospital of Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yahui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yuxuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hailong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Kunming Medical University, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Kunming Medical University, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4874-1305</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3359-2471</Identifier><AffiliationInfo><Affiliation>Jiangsu Provincial Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054804">Cathelicidins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018834">Chaperonin 60</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054804" MajorTopicYN="Y">Cathelicidins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018834" MajorTopicYN="N">Chaperonin 60</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="Y">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HSP60</Keyword><Keyword MajorTopicYN="N">antimicrobial peptide</Keyword><Keyword MajorTopicYN="N">cathelicidin</Keyword><Keyword MajorTopicYN="N">coxsackievirus</Keyword><Keyword MajorTopicYN="N">exosome</Keyword><Keyword MajorTopicYN="N">viral myocarditis</Keyword><Keyword MajorTopicYN="N">virus transmission</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36916989</ArticleId><ArticleId IdType="pmc">PMC10062171</ArticleId><ArticleId IdType="doi">10.1128/jvi.01433-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389–395. 10.1038/415389a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/415389a</ArticleId><ArticleId IdType="pubmed">11807545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bals R, Wang X, Zasloff M, Wilson JM. 1998. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 95:9541–9546. 10.1073/pnas.95.16.9541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.16.9541</ArticleId><ArticleId IdType="pmc">PMC21374</ArticleId><ArticleId IdType="pubmed">9689116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R. 1997. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 272:13088–13093. 10.1074/jbc.272.20.13088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.20.13088</ArticleId><ArticleId IdType="pubmed">9148921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Furio L, Mecheri R, van der Does AM, Lundeberg E, Saveanu L, Chen Y, van Endert P, Agerberth B, Diana J. 2015. Pancreatic beta cells limit autoimmune diabetes via an immunoregulatory antimicrobial peptide expressed under the influence of the gut microbiota. Immunity 43:304–317. 10.1016/j.immuni.2015.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.07.013</ArticleId><ArticleId IdType="pubmed">26253786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Meng P, Han Y, Shen C, Li B, Hakim MA, Zhang X, Lu Q, Rong M, Lai R. 2015. Mitochondrial DNA-LL-37 complex promotes atherosclerosis by escaping from autophagic recognition. Immunity 43:1137–1147. 10.1016/j.immuni.2015.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.10.018</ArticleId><ArticleId IdType="pubmed">26680206</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. 2004. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 172:1763–1767. 10.4049/jimmunol.172.3.1763.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.3.1763</ArticleId><ArticleId IdType="pubmed">14734759</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie SM, Gwyer Findlay E, McFarlane AJ, Fitch PM, Bottcher B, Colegrave N, Paras A, Jozwik A, Chiu C, Schwarze J, Davidson DJ. 2016. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol 196:2699–2710. 10.4049/jimmunol.1502478.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1502478</ArticleId><ArticleId IdType="pmc">PMC4777919</ArticleId><ArticleId IdType="pubmed">26873992</ArticleId></ArticleIdList></Reference><Reference><Citation>LeMessurier KS, Lin Y, McCullers JA, Samarasinghe AE. 2016. Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice. Antiviral Res 133:208–217. 10.1016/j.antiviral.2016.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.08.013</ArticleId><ArticleId IdType="pmc">PMC5903439</ArticleId><ArticleId IdType="pubmed">27531368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J. 2007. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res 5:410–415. 10.2174/157016207781023947.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157016207781023947</ArticleId><ArticleId IdType="pubmed">17627504</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. 2005. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 30:385–394. 10.1080/02713680590934111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02713680590934111</ArticleId><ArticleId IdType="pmc">PMC1497871</ArticleId><ArticleId IdType="pubmed">16020269</ArticleId></ArticleIdList></Reference><Reference><Citation>Alagarasu K, Patil PS, Shil P, Seervi M, Kakade MB, Tillu H, Salunke A. 2017. In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2. Peptides 92:23–30. 10.1016/j.peptides.2017.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2017.04.002</ArticleId><ArticleId IdType="pubmed">28400226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed A, Siman-Tov G, Keck F, Kortchak S, Bakovic A, Risner K, Lu TK, Bhalla N, de la Fuente-Nunez C, Narayanan A. 2019. Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections. Antiviral Res 164:61–69. 10.1016/j.antiviral.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.02.002</ArticleId><ArticleId IdType="pubmed">30738837</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotlieb N, Tachlytski I, Lapidot Y, Sultan M, Safran M, Ben-Ari Z. 2018. Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and production. Mol Med 24:53. 10.1186/s10020-018-0055-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-018-0055-0</ArticleId><ArticleId IdType="pmc">PMC6192355</ArticleId><ArticleId IdType="pubmed">30326825</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura T, Sugiyama N, Murayama A, Yamada N, Shiina M, Asabe S, Wakita T, Imawari M, Kato T. 2016. Antimicrobial peptide LL-37 attenuates infection of hepatitis C virus. Hepatol Res 46:924–932. 10.1111/hepr.12627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hepr.12627</ArticleId><ArticleId IdType="pubmed">26606891</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Wu J, Qin Z, Dong C, Yang H, Sun J, Xu W, Wei L. 2022. Endogenous cathelicidin is required for protection against ZIKV-caused testis damage via inactivating virons. Antiviral Res 198:105248. 10.1016/j.antiviral.2022.105248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105248</ArticleId><ArticleId IdType="pubmed">35038500</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlow PG, Findlay EG, Currie SM, Davidson DJ. 2014. Antiviral potential of cathelicidins. Future Microbiol 9:55–73. 10.2217/fmb.13.135.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.13.135</ArticleId><ArticleId IdType="pubmed">24328381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa FH, Casanova V, Findlay F, Stevens C, Svoboda P, Pohl J, Proudfoot L, Barlow PG. 2017. Cathelicidins display conserved direct antiviral activity towards rhinovirus. Peptides 95:76–83. 10.1016/j.peptides.2017.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2017.07.013</ArticleId><ArticleId IdType="pmc">PMC5577862</ArticleId><ArticleId IdType="pubmed">28764966</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Dai Y, Fu Y, Wang K, Yang Y, Li M, Xu W, Wei L. 2021. Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding. Antiviral Res 187:105021. 10.1016/j.antiviral.2021.105021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2021.105021</ArticleId><ArticleId IdType="pubmed">33508330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Xie W, Zhang L, Li D, Yu H, Xiong J, Peng J, Qiu J, Sheng H, He X, Zhang K. 2018. CVB3 nonstructural 2A protein modulates SREBP1a signaling via the MEK/ERK pathway. J Virol 92:e01060-18. 10.1128/JVI.01060-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01060-18</ArticleId><ArticleId IdType="pmc">PMC6258932</ArticleId><ArticleId IdType="pubmed">30258014</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenet M, N’Guyen Y, Mirand A, Henquell C, Lebreil A-L, Berri F, Bani-Sadr F, Lina B, Schuffenecker I, Andreoletti L, Mirand A, Henquell C, Mathieu M-L, Mezgueldi E, Verdan M, Motreff P, Lina B, Schuffenecker I, Fafi-Kremer S, Lepiller Q, Bruneval P, French Enterovirus Myocarditis Study Group . 2020. Major 5′-terminally deleted enterovirus populations modulate type I IFN response in acute myocarditis patients and in human cultured cardiomyocytes. Sci Rep 10:11947. 10.1038/s41598-020-67648-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67648-5</ArticleId><ArticleId IdType="pmc">PMC7371739</ArticleId><ArticleId IdType="pubmed">32686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung G, Luo H, Qiu Y, Yang D, McManus B. 2016. Myocarditis. Circ Res 118:496–514. 10.1161/CIRCRESAHA.115.306573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.306573</ArticleId><ArticleId IdType="pubmed">26846643</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhang H, Wang X, Guo J, Wei L, Song Y, Luo Y, Zhao Y, Subramaniam M, Spelsberg TC, Wang L, Xu W, Li M. 2021. Kruppel-like factor 10 protects against acute viral myocarditis by negatively regulating cardiac MCP-1 expression. Cell Mol Immunol 18:2236–2248. 10.1038/s41423-020-00539-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00539-x</ArticleId><ArticleId IdType="pmc">PMC8429749</ArticleId><ArticleId IdType="pubmed">32895486</ArticleId></ArticleIdList></Reference><Reference><Citation>Costafreda MI, Abbasi A, Lu H, Kaplan G. 2020. Exosome mimicry by a HAVCR1-NPC1 pathway of endosomal fusion mediates hepatitis A virus infection. Nat Microbiol 5:1096–1106. 10.1038/s41564-020-0740-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0740-y</ArticleId><ArticleId IdType="pmc">PMC7483988</ArticleId><ArticleId IdType="pubmed">32541946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ. 2013. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci USA 110:13109–13113. 10.1073/pnas.1221899110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1221899110</ArticleId><ArticleId IdType="pmc">PMC3740869</ArticleId><ArticleId IdType="pubmed">23878230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Zhang L, Zhang F, Tang T, Zhou Q, Feng C, Jin Y, Wu Z. 2017. Exosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection. PLoS Pathog 13:e1006611. 10.1371/journal.ppat.1006611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006611</ArticleId><ArticleId IdType="pmc">PMC5614653</ArticleId><ArticleId IdType="pubmed">28910400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan K-L, Li M-F, Cui F, Feng F, Kong L, Zhang F-H, Hao H, Yin M-X, Liu Y. 2019. Altered exosomal miR-181d and miR-30a related to the pathogenesis of CVB3 induced myocarditis by targeting SOCS3. Eur Rev Med Pharmacol Sci 23:2208–2215. 10.26355/eurrev_201903_17268.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_201903_17268</ArticleId><ArticleId IdType="pubmed">30915768</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson SM, Tsueng G, Sin J, Mangale V, Rahawi S, McIntyre LL, Williams W, Kha N, Cruz C, Hancock BM, Nguyen DP, Sayen MR, Hilton BJ, Doran KS, Segall AM, Wolkowicz R, Cornell CT, Whitton JL, Gottlieb RA, Feuer R. 2014. Coxsackievirus B exits the host cell in shed microvesicles displaying autophagosomal markers. PLoS Pathog 10:e1004045. 10.1371/journal.ppat.1004045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004045</ArticleId><ArticleId IdType="pmc">PMC3983045</ArticleId><ArticleId IdType="pubmed">24722773</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Enee E, Andre-Vallee C, Falcone M, Sun J, Diana J. 2022. Intestinal cathelicidin antimicrobial peptide shapes a protective neonatal gut microbiota against pancreatic autoimmunity. Gastroenterology 162:1288–1302. 10.1053/j.gastro.2021.12.272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.12.272</ArticleId><ArticleId IdType="pubmed">34973295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow LH, Gauntt CJ, McManus BM. 1991. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice: a pathologic characterization of heart tissue damage. Lab Invest 64:55–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">1990209</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Knowlton AA. 2007. HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway. Am J Physiol Heart Circ Physiol 292:H3052–H3056. 10.1152/ajpheart.01355.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.01355.2006</ArticleId><ArticleId IdType="pubmed">17307989</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik ZA, Kott KS, Poe AJ, Kuo T, Chen L, Ferrara KW, Knowlton AA. 2013. Cardiac myocyte exosomes: stability, HSP60, and proteomics. Am J Physiol Heart Circ Physiol 304:H954–H965. 10.1152/ajpheart.00835.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00835.2012</ArticleId><ArticleId IdType="pmc">PMC3625894</ArticleId><ArticleId IdType="pubmed">23376832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SC, Stice JP, Chen L, Jung JS, Gupta S, Wang Y, Baumgarten G, Trial J, Knowlton AA. 2009. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 105:1186–1195. 10.1161/CIRCRESAHA.109.209643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.109.209643</ArticleId><ArticleId IdType="pmc">PMC2949276</ArticleId><ArticleId IdType="pubmed">19875724</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin U, Jarasch N, Nestler M, Rassmann A, Munder T, Seitz S, Zell R, Wutzler P, Henke A. 2007. Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3. Apoptosis 12:525–533. 10.1007/s10495-006-0015-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-006-0015-y</ArticleId><ArticleId IdType="pubmed">17211569</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, Leung DY. 2006. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 24:341–348. 10.1016/j.immuni.2006.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.02.006</ArticleId><ArticleId IdType="pubmed">16546102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. 2008. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 181:7090–7099. 10.4049/jimmunol.181.10.7090.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.10.7090</ArticleId><ArticleId IdType="pmc">PMC2596683</ArticleId><ArticleId IdType="pubmed">18981129</ArticleId></ArticleIdList></Reference><Reference><Citation>Levinson P, Choi RY, Cole AL, Hirbod T, Rhedin S, Payne B, Guthrie BL, Bosire R, Cole AM, Farquhar C, Broliden K. 2012. HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. PLoS One 7:e31996. 10.1371/journal.pone.0031996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031996</ArticleId><ArticleId IdType="pmc">PMC3289637</ArticleId><ArticleId IdType="pubmed">22389677</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaneda-Sanchez JI, Dominguez-Martinez DA, Olivar-Espinosa N, Garcia-Perez BE, Lorono-Pino MA, Luna-Herrera J, Salazar MI. 2016. Expression of antimicrobial peptides in human monocytic cells and neutrophils in response to dengue virus type 2. Intervirology 59:8–19. 10.1159/000446282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000446282</ArticleId><ArticleId IdType="pubmed">27318958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez M, Meza-Sanchez D, Garcia-Cordero J, Bustos-Arriaga J, Velez-Del Valle C, Marsch-Moreno M, Castro-Jimenez T, Flores-Romo L, Santos-Argumedo L, Gutierrez-Castaneda B, Cedillo-Barron L. 2018. Human keratinocyte cultures (HaCaT) can be infected by DENV, triggering innate immune responses that include IFNλ and LL37. Immunobiology 223:608–617. 10.1016/j.imbio.2018.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2018.07.006</ArticleId><ArticleId IdType="pubmed">30007822</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean RE, O’Brien LM, Thwaite JE, Fox MA, Atkins H, Ulaeto DO. 2010. A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes. Peptides 31:1966–1972. 10.1016/j.peptides.2010.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2010.07.028</ArticleId><ArticleId IdType="pubmed">20705109</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie SM, Findlay EG, McHugh BJ, Mackellar A, Man T, Macmillan D, Wang H, Fitch PM, Schwarze J, Davidson DJ. 2013. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One 8:e73659. 10.1371/journal.pone.0073659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0073659</ArticleId><ArticleId IdType="pmc">PMC3758310</ArticleId><ArticleId IdType="pubmed">24023689</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi S, Tecle T, Verma A, Crouch E, White M, Hartshorn KL. 2013. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J Gen Virol 94:40–49. 10.1099/vir.0.045013-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.045013-0</ArticleId><ArticleId IdType="pmc">PMC3542722</ArticleId><ArticleId IdType="pubmed">23052388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi S, Wang G, White M, Qi L, Taubenberger J, Hartshorn KL. 2015. Antiviral activity of the human cathelicidin, LL-37, and derived peptides on seasonal and pandemic influenza A viruses. PLoS One 10:e0124706. 10.1371/journal.pone.0124706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0124706</ArticleId><ArticleId IdType="pmc">PMC4409069</ArticleId><ArticleId IdType="pubmed">25909853</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Hensley L, McKnight KL, Hu F, Madden V, Ping L, Jeong SH, Walker C, Lanford RE, Lemon SM. 2013. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 496:367–371. 10.1038/nature12029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12029</ArticleId><ArticleId IdType="pmc">PMC3631468</ArticleId><ArticleId IdType="pubmed">23542590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kytö V, Lapatto R, Lakkisto P, Saraste A, Voipio-Pulkki LM, Vuorinen T, Pulkki K. 2004. Glutathione depletion and cardiomyocyte apoptosis in viral myocarditis. Eur J Clin Invest 34:167–175. 10.1111/j.1365-2362.2004.01313.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2004.01313.x</ArticleId><ArticleId IdType="pubmed">15025674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A, Morosky SA, Delorme-Axford E, Dybdahl-Sissoko N, Oberste MS, Wang T, Coyne CB. 2011. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog 7:e1001311. 10.1371/journal.ppat.1001311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001311</ArticleId><ArticleId IdType="pmc">PMC3059221</ArticleId><ArticleId IdType="pubmed">21436888</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Zhang L, Odenwald MA, Shen L, Turner JR, Bergelson JM. 2015. Expression of human decay-accelerating factor on intestinal epithelium of transgenic mice does not facilitate infection by the enteral route. J Virol 89:4311–4318. 10.1128/JVI.03468-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03468-14</ArticleId><ArticleId IdType="pmc">PMC4442383</ArticleId><ArticleId IdType="pubmed">25653430</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VK, Chan CC, Leung HC, Fai N, Lin YP, Zhang AJ, Jin D-Y, Yuen K-Y, Zheng B-J. 2016. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep 6:22008. 10.1038/srep22008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22008</ArticleId><ArticleId IdType="pmc">PMC4766503</ArticleId><ArticleId IdType="pubmed">26911565</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle LM, Wang MZ. 2019. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells 8:727. 10.3390/cells8070727.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8070727</ArticleId><ArticleId IdType="pmc">PMC6678302</ArticleId><ArticleId IdType="pubmed">31311206</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei X, Li Z, Yang D, Kong X, Lu X, Shen Y, Li X, Xie S, Wang J, Zhao Y, Sun Y, Zhang J, Ye Z, Wang J, Cai Z. 2021. Neddylation of Coro1a determines the fate of multivesicular bodies and biogenesis of extracellular vesicles. J Extracell Vesicles 10:e12153. 10.1002/jev2.12153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jev2.12153</ArticleId><ArticleId IdType="pmc">PMC8500273</ArticleId><ArticleId IdType="pubmed">34623756</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Yan K, Wei L, Yang J, Lu C, Xiong F, Zheng C, Xu W. 2015. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis. Antiviral Res 123:50–61. 10.1016/j.antiviral.2015.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.09.001</ArticleId><ArticleId IdType="pubmed">26343012</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Xiong S. 2021. Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-CoV-2 infection. J Control Release 335:584–595. 10.1016/j.jconrel.2021.05.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.05.049</ArticleId><ArticleId IdType="pmc">PMC8172277</ArticleId><ArticleId IdType="pubmed">34089793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Zou C, Wang X, Huang C, Feng T, Pan W, Wu Q, Wang P, Dai J. 2018. Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3. PLoS Pathog 14:e1007287. 10.1371/journal.ppat.1007287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007287</ArticleId><ArticleId IdType="pmc">PMC6126873</ArticleId><ArticleId IdType="pubmed">30142214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>